FDA MUMS Animal Drug Development Grants

The FDA MUMS Animal Drug Development Grants program sits under the Food and Drug Administration's Center for Veterinary Medicine and funds sponsors working on FDA-designated Minor Use Minor Species animal drugs. Its purpose is straightforward: help sponsors complete the studies needed to win approval for treatments that serve uncommon diseases in major species or any disease in minor species. Awards are capped at $250,000 per year. Routine studies can run for up to two years and reach $500,000 total, while toxicology studies can run for up to three years and reach $750,000 total. The program has funded 72 studies totaling $8.4 million since inception, and applications are filed through NIH ASSIST or Grants.gov under NOFO PAR-24-216 and R01 mechanism rules. The published application windows show the program remains active, with a second FY2026 period and a first FY2027 period announced on May 22, 2026. Applicants need Designated MUMS status for the specific drug and indication, so this is not a general animal-health grant. The program is best suited to sponsors and research partners with a defined regulatory path and a study package that can support approval. The funded indications in the source set include parasitic and bacterial diseases in fish, cancers in dogs, and use cases involving horses, pheasants, and goats.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.